Trial · NCT05826015
AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
NCT05826015, Phase 1, Withdrawn, Washington University School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer. Trials, record NCT05826015. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05826015
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
- NCT number
- NCT05826015
- Status
- Withdrawn
- Phases
- Phase 1
- Enrollment
- 0 participants, actual
- Lead sponsor
- Washington University School of Medicine
- Conditions
- Recurrent High Grade Uterine Cancer
- Interventions
- Paclitaxel, Batiraxcept
- First posted
- 2023-04-24
- Last updated
- 2024-10-02
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Frequency and severity of treatment-emergent adverse events | From start of treatment though 30 days after the last dose of AVB-500 (estimated to be 31 weeks) | -Graded by CTCAE v.5. |
| Secondary | Serum sAXL and GAS6 ratio | At baseline | |
| Secondary | Pharmacokinetic (PK) parameters (including Cmax) as determined from AVB-500 serum levels | Cycle 1 Day 1 pre-infusion, Cycle 1 Day 1 post-infusion, Cycle 1 Day 15 pre-infusion, and subsequent cycles day 1 pre-infusions (each cycle is 21 days) | |
| Secondary | Pharmacokinetic (PK) parameters (including Tmax) as determined from AVB-500 serum levels | Cycle 1 Day 1 pre-infusion, Cycle 1 Day 1 post-infusion, Cycle 1 Day 15 pre-infusion, and subsequent cycles day 1 pre-infusions (each cycle is 21 days) | |
| Secondary | Pharmacodynamic effects as determined by changes from baseline in serum GAS6 levels | Cycle 1 Day 1 pre-infusion, Cycle 1 Day 1 post-infusion, Cycle 1 Day 15 pre-infusion, and subsequent cycles day 1 pre-infusions (each cycle is 21 days) | |
| Secondary | Overall response rate (ORR) | Through completion of treatment (estimated to be 27 weeks) | -Defined as the proportion of subjects who have a partial or complete response to therapy |
| Secondary | Progression-free survival (PFS) | Through completion of follow-up (estimated to be 5 years and 27 weeks) | -Defined as the time from start of treatment to the first radiologically documented disease progression, or death, whichever comes first. The alive patients without radiologically documented disease progression are censored at the last follow-up. |
| Secondary | Recommended Phase 2 dose (RP2D) of AVB-500 in combination with paclitaxel | Through completion of cycle 1 (cycle=21 days) for all patients (estimated to be 48 months and 3 weeks) | |
| Secondary | Incidence of anti-drug antibodies (ADA) | Day 1 of each cycle (cycle-21 days) and end of treatment (estimated to be 27 weeks) | |
| Secondary | Overall survival (OS) | Through completion of follow-up (estimated to be 5 years and 27 weeks) | -Defined as the time from start of treatment to death. The alive patients are censored at the last follow-up. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05826015
GET https://conductscience.org/api/trials/v1/NCT05826015/registered